

Biocon Biologics Germany GMBH
BALANCE SHEET AS AT MARCH 31, 2024

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	<u>Notes</u>	<u>March 31,</u> <u>2024</u>
ASSETS		
Financial assets		
(i) Trade receivables	1	3,533
(ii) Cash and cash equivalents	2	708
Other current assets	3	<u>2</u>
Total current assets		4,243
TOTAL		
		<u><u>4,243</u></u>
EQUITY AND LIABILITIES		
Equity		
Equity share capital	4	25
Other equity	5	<u>114</u>
Total equity		139
Current liabilities		
Financial liabilities		
(i) Trade payables	6	2,986
Income-tax liability (net)		49
Provisions	7	372
Other current liabilities	8	<u>697</u>
Total current liabilities		4,104
TOTAL		
		<u><u>4,243</u></u>

Biocon Biologics Germany GMBH**STATEMENT OF PROFIT AND LOSS FOR THE PERIOD ENDED MARCH 31, 2024**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	<u>Notes</u>	<u>Period ended March 31, 2024</u>
Income		
Other operating income	9	6,743
Total revenue (I)		<u>6,743</u>
Expenses		
Employee benefits expense	10	4,654
Other expenses	11	1,926
Total expenses (II)		<u>6,580</u>
Profit before tax		<u>163</u>
Tax expense		
Current tax		49
Deferred Tax		-
Total tax expense		<u>49</u>
Profit for the period		<u><u>114</u></u>

Biocon Biologics Germany GMBH**STATEMENT OF CASH FLOWS FOR THE PERIOD ENDED MARCH 31, 2024**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	Period ended March 31, 2023
I Cash flows from operating activities	
Profit after tax	114
Movements in working capital	
Decrease/(Increase) in trade receivables	(3,533)
(Increase) in loans and advances and other assets	(2)
Increase in trade payable, other liabilities and provisions	4,055
Net cash flow generated from operating activities	683
II Cash flows from investing activities	
Net cash flow from investing activities	-
III Cash flows from financing activities	
Proceeds from issue of equity shares	25
Net cash flow generated from financing activities	25
IV Net increase in cash and cash equivalents (I + II + III)	708
V Cash and cash equivalents at the end of the year	708
Reconciliation of cash and cash equivalents as per statement of cash flow	
Cash and cash equivalents	
Balances with banks - on current accounts	708
Total cash and cash equivalents [Refer note 2]	708

Biocon Biologics Germany GMBH**Notes to financial statements for the period ended March 31, 2024**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

**March 31,
2024****1. Trade receivables****Other Receivables**

Unsecured, considered good

3,533

3,533**2. Cash and cash equivalents**

Balances with banks:

On current accounts

708

708**3. Other current assets**

Prepayments

2

2**4. Share capital**

25,000 Equity share of EUR 1 each

25

25**5. Other equity****Surplus/(deficit) in the statement of profit and loss**

Balance as per the last financial statements

-

Profit / (Loss) for the period

114

Net surplus/(deficit) in the statement of profit and loss**114****6. Trade payables****2,986****7. Provisions****Current**

Compensated absences

372

372**8. Other liabilities****(a) Current liabilities**

Statutory liabilities

697

697

Biocon Biologics Germany GMBH**Notes to financial statements for the period ended March 31, 2024**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	Period ended March 31, 2024
9. Other operating income	
Foreign exchange fluctuations, net	(1)
Support service cross charge to Group Companies	6,744
	<u>6,743</u>
10. Employee benefits expense	
Salaries, wages and bonus	4,616
Staff welfare expenses	38
	<u>4,654</u>
11. Other expenses	
Rent	453
Legal and professional fees	352
Repair and Maintenance	32
Travelling and conveyance	427
Sales promotion expenses	478
Printing and stationery	114
Communication expenses	45
Miscellaneous expenses	25
	<u>1,926</u>